NASDAQ:DYN

Dyne Therapeutics (DYN) Stock Price, News & Analysis

Dyne Therapeutics logo
$15.87 -0.15 (-0.94%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$15.88 +0.01 (+0.06%)
As of 11/18/2026 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Dyne Therapeutics Stock (NASDAQ:DYN)

Advanced

Key Stats

Today's Range
$15.87
▼
$16.56
50-Day Range
$14.25
▼
$18.62
52-Week Range
$14.00
▼
$27.31
Volume
2.93 million shs
Average Volume
2.34 million shs
Market Capitalization
$2.97 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.29
Consensus Rating
Moderate Buy

Company Overview

Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven muscle diseases. Its research uses the FORCE platform, which is designed to deliver oligonucleotide medicines to muscle tissue.

The company’s programs include DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping. Dyne has also pursued a program for facioscapulohumeral muscular dystrophy. Its therapies remain in development, and the company does not have an approved product.

Founded in 2017 and based in Waltham, Massachusetts, Dyne is led by President and Chief Executive Officer John Cox. Its research and clinical development activities are primarily based in the United States.

AI Generated. May Contain Errors.

Dyne Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

DYN MarketRank™: 
3.225762341035 of 5 stars

Dyne Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 573rd out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Dyne Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 1 strong buy rating, 11 buy ratings, 2 hold ratings, and 2 sell ratings.

  • Upside Potential

    Dyne Therapeutics has a consensus price target of $31.29, representing about 97.1% upside from its current price of $15.87.

  • Amount of Analyst Coverage

    Dyne Therapeutics has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Dyne Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Dyne Therapeutics are expected to grow in the coming year, from ($3.81) to ($3.65) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Dyne Therapeutics is -4.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Dyne Therapeutics is -4.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Dyne Therapeutics has a P/B Ratio of 3.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    14.37% of the float of Dyne Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Dyne Therapeutics has a short interest ratio ("days to cover") of 10.81, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Dyne Therapeutics has recently decreased by 4.28%, indicating that investor sentiment is improving.
  • Dividend Yield

    Dyne Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Dyne Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Dyne Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Dyne Therapeutics this week, compared to 6 articles on an average week.
  • Search Interest

    Only 7 people have searched for DYN on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Dyne Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Dyne Therapeutics insiders have sold 612.88% more of their company's stock than they have bought. Specifically, they have bought $40,000.00 in company stock and sold $285,151.00 in company stock.

  • Percentage Held by Insiders

    9.46% of the stock of Dyne Therapeutics is held by insiders.

  • Percentage Held by Institutions

    96.68% of the stock of Dyne Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Dyne Therapeutics' insider trading history.
Receive DYN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DYN Stock News Headlines

Dyne Therapeutics (NASDAQ:DYN) CFO Sells 1,991 Shares of Stock
Under 3 cents a night
Bill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.tc pixel
HC Wainwright Expects Weaker Earnings for Dyne Therapeutics
Brokers Set Expectations for DYN Q2 Earnings
See More Headlines

DYN Stock Analysis - Frequently Asked Questions

Dyne Therapeutics' stock was trading at $19.56 at the start of the year. Since then, DYN stock has decreased by 18.9% and is now trading at $15.87.

Dyne Therapeutics, Inc. (NASDAQ:DYN) issued its quarterly earnings results on Thursday, November, 5th. The company reported ($1.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.91) by $0.15.

Dyne Therapeutics (DYN) raised $208 million in an initial public offering on Thursday, September 17th 2020. The company issued 12,251,578 shares at $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel served as the underwriters for the IPO.

Dyne Therapeutics' top institutional investors include State Street Corp (4.36%), Goldman Sachs Group Inc. (1.10%), Aberdeen Group plc (0.72%) and Marshall Wace LLP (0.37%). Insiders that own company stock include Venture Fund Xi LP Atlas, Jason P Rhodes, John Cox, Oxana Beskrovnaya, Douglas Kerr, Johanna Friedl-Naderer, Wildon Farwell, Susanna Gatti High, Richard William Scalzo, Erick Lucera, Dirk Kersten, Brian S Posner and Carlo Incerti.
View institutional ownership trends
.

Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Dyne Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Tesla (TSLA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Definium Therapeutics (DFTX) and Alphabet (GOOG).

Company Calendar

Last Earnings
11/05/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:DYN
Previous Symbol
NYSE:DYN
CIK
1818794
Employees
258
Year Founded
2018

Price Target and Rating

High Price Target
$50.00
Low Price Target
$10.00
Potential Upside/Downside
+97.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.69
Research Coverage
16 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.63)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$446.21 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-69.73%
Return on Assets
-53.82%

Debt

Debt-to-Equity Ratio
0.21
Current Ratio
12.99
Quick Ratio
12.99

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.97 per share
Price / Book
3.19

Miscellaneous

Outstanding Shares
187,330,000
Free Float
169,607,000
Market Cap
$2.97 billion
Optionable
Optionable
Beta
1.22

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

This page (NASDAQ:DYN) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners